Structural Heart

The Journal of the Heart Team

Volume 2, 2018 - Issue 3

Views

CrossRef citations to date

Altmetric

Original Research

Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device

Denise TodaroDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Marco BarbantiDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, ItalyCorrespondence[email protected]

https://orcid.org/0000-0002-4903-5437

, MD

Andrea PicciDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Giuliano CostaDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Emanuela Di SimoneDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Simona GulinoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Piera CapranzanoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Gerlando PilatoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Ketty La SpinaDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Wanda DesteDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Antonino IndelicatoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Daniela GiannazzoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Paolo D’ArrigoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Maria Cristina PortelliDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Davide CapodannoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Sebastiano ImmèDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Claudia TamburinoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Martina PatanèDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD,

Carmelo SgroiDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy

, MD &

Corrado TamburinoDivision of Cardiology–Ferrarotto Hospital, University of Catania, Catania, Italy;ETNA Foundation, Catania, Italy

, MD, PhD show all

ABSTRACT

Background: To assess early and mid-term efﬁcacy of transcatheter aortic valve replacement (TAVR) using the new-generation CoreValve Evolut R (Medtronic Inc., Galway, Ireland).

Methods: This is a prospective, single-center study. All consecutive patients undergoing TAVR with 23-, 26-, 29-, 34-mm Evolut R valve were included. In a secondary analysis, patients undergoing Evolut R implantation were compared using the propensity score method with a historical cohort of patients who underwent CoreValve implantation in our institution.

Results: From March 2015 to September 2017, a total of 320 patients with a median age of 81.1 years (IQR 77–84) and mean STS score of 4.9 ± 3.1% were treated. Device success was obtained in 300 patients (93.8%). Effective recapture and repositioning of the valve due to initial suboptimal deployment was accomplished in 40 patients (12.5%). Post-TAVR transthoracic echocardiogram showed a reduction in mean gradient from 49.1 ± 18.2 mmHg to 7.6 ± 0.4 mmHg (p < 0.001). Moderate paravalvular regurgitation (PVR) was observed in 4.2% patients. No patient had severe PVR. At 30-day, all-cause and cardiovascular mortality rates were 2.2% and 1.9%, respectively; disabling stroke occurred in 5 patients (1.6%). Life-threatening and major bleeding occurred in 16 (5.0%) and 42 (13.1%) patients, respectively. Pacemaker implantation rate was 12.6%. Compared with the CoreValve, Evolut R use was associated with higher device success (92.8% vs. 79.7%, p < 0.001) and lower rates of moderate or severe PVR (2.1% vs. 14.4%, p < 0.001), minor vascular complications (4.9% vs. 14.5%, p < 0.001), and pacemaker implantation (13.5% vs. 21.0%, p = 0.026).

Conclusion: In this prospective, single-center study, TAVR using the new-generation self-expanding Evolut R system, was associated with high device success rate, excellent hemodynamics, and low early complications rates.

KEYWORDS:

Disclosure statements

Marco Barbanti is a consultant for Edwards Lifesciences. All other authors report no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device

Related Research Data

Information for

Open access

Opportunities

Help and information

Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device

ABSTRACT

Disclosure statements

Reprints and Corporate Permissions

Academic Permissions

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature